Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study


Aydin O., Sonusen S. D., Buyukkuscu A., Sahin S. B., Kalkan S., Ozturk A. E., ...Daha Fazla

Journal of Cancer, cilt.17, sa.10, ss.1733-1743, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 10
  • Basım Tarihi: 2026
  • Doi Numarası: 10.7150/jca.138530
  • Dergi Adı: Journal of Cancer
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Health Research Premium Collection (ProQuest)
  • Sayfa Sayıları: ss.1733-1743
  • Anahtar Kelimeler: metastatic colorectal cancer, FOLFIRI, bevacizumab, aflibercept, second-line therapy
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: The optimal anti-angiogenic strategy in the second-line treatment of metastatic colorectal cancer (mCRC) after progression on first-line FOLFOX plus bevacizumab remains unclear. We aimed to compare the efficacy and safety of FOLFIRI combined with bevacizumab or aflibercept in this well-defined clinical setting. Methods: In this retrospective single-center study, 152 patients with mCRC who progressed after at least four cycles of first-line FOLFOX plus bevacizumab were included. Of these, 92 patients received FOLFIRI plus bevacizumab and 60 received FOLFIRI plus aflibercept as second-line therapy. Stabilized inverse probability of treatment weighting (IPTW) was applied to account for baseline differences between treatment groups. PFS and OS were evaluated using IPTW-weighted Kaplan–Meier and Cox regression analyses. Results: No statistically significant difference was observed between the bevacizumab and aflibercept groups for PFS (HR: 1.302, 95% CI: 0.929–1.825, p=0.125) or OS (HR: 1.212, 95% CI: 0.846–1.736, p=0.295) in the IPTW-weighted analyses. Treatment type was not independently associated with PFS or OS in multivariate analyses. Grade 3–4 toxicities were observed in both groups, with neutropenia being the most common; thrombocytopenia and neutropenia were numerically more frequent in the aflibercept group. Conclusion: No statistically significant differences in efficacy were observed between FOLFIRI plus bevacizumab and FOLFIRI plus aflibercept in patients with mCRC progressing after first-line FOLFOX plus bevacizumab. Both strategies represent reasonable second-line options in this setting, highlighting the need for prospective studies to define the optimal sequencing of anti-angiogenic therapies.